<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font22 { font-size : 22; } .font23 { font-size : 23; } .font25 { font-size : 25; } .font27 { font-size : 27; } .font28 { font-size : 28; } .font31 { font-size : 31; }</style>
 <body>
  <p>
   <span class="font31">atopic </span>
   <span class="font28">treatment </span>
   <span class="font27">use </span>
   <span class="font25">skin </span>
   <span class="font23">dermatitis </span>
   <span class="font23">patients </span>
   <span class="font22">Dermatol </span>
   <span class="font19">AD. </span>
   <span class="font19">therapy </span>
   <span class="font18">children </span>
   <span class="font18">recommended </span>
   <span class="font18">topical </span>
   <span class="font18">management </span>
   <span class="font18">Consensus </span>
   <span class="font17">Level </span>
   <span class="font17">Recommendation </span>
   <span class="font17">clinical </span>
   <span class="font17">used </span>
   <span class="font16">effective </span>
   <span class="font16">AD, </span>
   <span class="font16">severe </span>
   <span class="font16">{border-style </span>
   <span class="font15">dermatitis: </span>
   <span class="font15">disease </span>
   <span class="font15">mJ/cm </span>
   <span class="font15">px;} </span>
   <span class="font15">#ffffff;} </span>
   <span class="font15">Indian </span>
   <span class="font15">criteria </span>
   <span class="font15">long-term </span>
   <span class="font14">food </span>
   <span class="font14">study </span>
   <span class="font14">systemic </span>
   <span class="font14">TCS </span>
   <span class="font14">effects </span>
   <span class="font14">efficacy </span>
   <span class="font14">evidence </span>
   <span class="font14">studies </span>
   <span class="font14">India </span>
   <span class="font14">acute </span>
   <span class="font14">adults </span>
   <span class="font14">considered </span>
   <span class="font14">eczema </span>
   <span class="font14">factors </span>
   <span class="font14">proactive </span>
   <span class="font14">safety </span>
   <span class="font14">years </span>
   <span class="font14">Evidence </span>
   <span class="font14">controlled </span>
   <span class="font14">corticosteroids </span>
   <span class="font14">moderate </span>
   <span class="font14">patient </span>
   <span class="font14">pediatric </span>
   <span class="font14">severity </span>
   <span class="font13">Atopic </span>
   <span class="font13">Table </span>
   <span class="font13">moisturizer </span>
   <span class="font13">trial </span>
   <span class="font13">trials </span>
   <span class="font13">However, </span>
   <span class="font13">RCTs </span>
   <span class="font13">TCSs </span>
   <span class="font13">based </span>
   <span class="font13">effect </span>
   <span class="font13">guidelines </span>
   <span class="font13">randomized </span>
   <span class="font13">reduce </span>
   <span class="font13">review </span>
   <span class="font13">symptoms </span>
   <span class="font13">Acad </span>
   <span class="font13">DEBM </span>
   <span class="font13">Dermatology </span>
   <span class="font13">Evidence: </span>
   <span class="font13">IgE </span>
   <span class="font13">TCIs </span>
   <span class="font13">age </span>
   <span class="font13">risk </span>
   <span class="font13">role </span>
   <span class="font12">Allergy </span>
   <span class="font12">Department </span>
   <span class="font12">Dermatology, </span>
   <span class="font12">Long-term </span>
   <span class="font12">Skin </span>
   <span class="font12">acid </span>
   <span class="font12">adult </span>
   <span class="font12">diagnosis </span>
   <span class="font12">dose </span>
   <span class="font12">include </span>
   <span class="font12">literature </span>
   <span class="font12">recommendations </span>
   <span class="font12">recommended. </span>
   <span class="font12">shown </span>
   <span class="font12">IL-, </span>
   <span class="font12">Topical </span>
   <span class="font12">[], </span>
   <span class="font12">and/or </span>
   <span class="font12">available </span>
   <span class="font12">common </span>
   <span class="font12">high </span>
   <span class="font12">meta-analysis </span>
   <span class="font12">oral </span>
   <span class="font12">px; </span>
   <span class="font12">suggested </span>
   <span class="font12">support </span>
   <span class="font12">tacrolimus </span>
   <span class="font12">twice </span>
   <span class="font12">versus </span>
   <span class="font12">{font-family </span>
   <span class="font12">AD.[ </span>
   <span class="font12">Clin </span>
   <span class="font12">CsA </span>
   <span class="font12">Hanifin </span>
   <span class="font12">RCT </span>
   <span class="font12">allergens </span>
   <span class="font12">anti-inflammatory </span>
   <span class="font12">appropriate </span>
   <span class="font12">cells </span>
   <span class="font12">chronic </span>
   <span class="font12">course </span>
   <span class="font12">cream </span>
   <span class="font12">font-size </span>
   <span class="font12">history </span>
   <span class="font12">including </span>
   <span class="font12">maintenance </span>
   <span class="font12">moisturizers </span>
   <span class="font12">prevention </span>
   <span class="font12">safe </span>
   <span class="font12">short </span>
   <span class="font11">Class </span>
   <span class="font11">Efficacy </span>
   <span class="font11">Guidelines </span>
   <span class="font11">adverse </span>
   <span class="font11">allergy </span>
   <span class="font11">as, </span>
   <span class="font11">barrier </span>
   <span class="font11">calcineurin </span>
   <span class="font11">childhood </span>
   <span class="font11">consensus </span>
   <span class="font11">daily </span>
   <span class="font11">double; </span>
   <span class="font11">duration </span>
   <span class="font11">emollient </span>
   <span class="font11">flares </span>
   <span class="font11">guideline </span>
   <span class="font11">helpful </span>
   <span class="font11">infants </span>
   <span class="font11">low </span>
   <span class="font11">oil </span>
   <span class="font11">onset </span>
   <span class="font11">phototherapy </span>
   <span class="font11">proposed </span>
   <span class="font11">published </span>
   <span class="font11">randomized, </span>
   <span class="font11">serum </span>
   <span class="font11">short-term </span>
   <span class="font11">suggest </span>
   <span class="font11">term </span>
   <span class="font11">time </span>
   <span class="font11">water </span>
   <span class="font11">Academy </span>
   <span class="font11">Azathioprine </span>
   <span class="font11">Bieber </span>
   <span class="font11">Diagnostic </span>
   <span class="font11">IL- </span>
   <span class="font11">Phototherapy </span>
   <span class="font11">Rajka </span>
   <span class="font11">Systematic </span>
   <span class="font11">TCI </span>
   <span class="font11">Venereol </span>
   <span class="font11">agents </span>
   <span class="font11">allergic </span>
   <span class="font11">antihistamines </span>
   <span class="font11">application </span>
   <span class="font11">area </span>
   <span class="font11">associated </span>
   <span class="font11">avoided. </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">care </span>
   <span class="font11">cyclosporin </span>
   <span class="font11">data </span>
   <span class="font11">double-blind, </span>
   <span class="font11">early </span>
   <span class="font11">especially </span>
   <span class="font11">evidence-based </span>
   <span class="font11">first-line </span>
   <span class="font11">flares. </span>
   <span class="font11">frequency </span>
   <span class="font11">generally </span>
   <span class="font11">immunoglobulin </span>
   <span class="font11">important </span>
   <span class="font11">infection. </span>
   <span class="font11">inhibitor </span>
   <span class="font11">inhibitors </span>
   <span class="font11">intermittent </span>
   <span class="font11">levels </span>
   <span class="font11">limited </span>
   <span class="font11">long </span>
   <span class="font11">moderate-to-severe </span>
   <span class="font11">optimal </span>
   <span class="font11">option </span>
   <span class="font11">personal </span>
   <span class="font11">pimecrolimus </span>
   <span class="font11">placebo-controlled </span>
   <span class="font11">quality </span>
   <span class="font11">reduces </span>
   <span class="font11">results </span>
   <span class="font11">severity. </span>
   <span class="font11">showed </span>
   <span class="font11">significant </span>
   <span class="font11">signs </span>
   <span class="font11">solid; </span>
   <span class="font11">specific </span>
   <span class="font11">steroid-sparing </span>
   <span class="font11">supplementation </span>
   <span class="font11">treatment. </span>
   <span class="font11">trigger </span>
   <span class="font11">wrap </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font11">"atopic </span>
   <span class="font11">Bathing </span>
   <span class="font11">Bengal, </span>
   <span class="font11">Boguniewicz </span>
   <span class="font11">British </span>
   <span class="font11">Cochrane </span>
   <span class="font11">Cyclosporine </span>
   <span class="font11">Dupilumab </span>
   <span class="font11">Epidemiology </span>
   <span class="font11">Expert </span>
   <span class="font11">Food </span>
   <span class="font11">Hospital, </span>
   <span class="font11">Immunol </span>
   <span class="font11">Line </span>
   <span class="font11">Med </span>
   <span class="font11">National </span>
   <span class="font11">SCORAD </span>
   <span class="font11">Society </span>
   <span class="font11">Therapy </span>
   <span class="font11">UVA </span>
   <span class="font11">WWT </span>
   <span class="font11">West </span>
   <span class="font11">Wet </span>
   <span class="font11">Williams </span>
   <span class="font11">acetonide </span>
   <span class="font11">antibiotic </span>
   <span class="font11">antibiotics </span>
   <span class="font11">applied </span>
   <span class="font11">approved </span>
   <span class="font11">areas </span>
   <span class="font11">assessment </span>
   <span class="font11">avoidance </span>
   <span class="font11">avoided </span>
   <span class="font11">azathioprine </span>
   <span class="font11">bacterial </span>
   <span class="font11">bath </span>
   <span class="font11">bathing </span>
   <span class="font11">benefit </span>
   <span class="font11">body </span>
   <span class="font11">bold </span>
   <span class="font11">butyrate </span>
   <span class="font11">cause </span>
   <span class="font11">children, </span>
   <span class="font11">children. </span>
   <span class="font11">choice </span>
   <span class="font11">clinically </span>
   <span class="font11">commonly </span>
   <span class="font11">contact </span>
   <span class="font11">courier; </span>
   <span class="font11">day </span>
   <span class="font11">decrease </span>
   <span class="font11">degree </span>
   <span class="font11">dermatitis, </span>
   <span class="font11">dermatology </span>
   <span class="font11">developed </span>
   <span class="font11">diagnostic </span>
   <span class="font11">disease. </span>
   <span class="font11">doses </span>
   <span class="font11">dry </span>
   <span class="font11">dupilumab </span>
   <span class="font11">eczema, </span>
   <span class="font11">em; </span>
   <span class="font11">established </span>
   <span class="font11">family </span>
   <span class="font11">features </span>
   <span class="font11">flare </span>
   <span class="font11">following </span>
   <span class="font11">free </span>
   <span class="font11">groups </span>
   <span class="font11">improve </span>
   <span class="font11">improvement </span>
   <span class="font11">interventions </span>
   <span class="font11">itch </span>
   <span class="font11">major </span>
   <span class="font11">members </span>
   <span class="font11">mg/kg/day) </span>
   <span class="font11">mild </span>
   <span class="font11">observed </span>
   <span class="font11">ointment </span>
   <span class="font11">physician </span>
   <span class="font11">population, </span>
   <span class="font11">potential </span>
   <span class="font11">prevent </span>
   <span class="font11">produce </span>
   <span class="font11">products </span>
   <span class="font11">provided </span>
   <span class="font11">pruritus </span>
   <span class="font11">pt;} </span>
   <span class="font11">recalcitrant </span>
   <span class="font11">regarding </span>
   <span class="font11">reported </span>
   <span class="font11">response </span>
   <span class="font11">similar </span>
   <span class="font11">thiopurine </span>
   <span class="font11">total </span>
   <span class="font11">treatment, </span>
   <span class="font11">type </span>
   <span class="font11">unresponsive </span>
   <span class="font11">vitamin </span>
   <span class="font11">weekly </span>
   <span class="font11">years) </span>
  </p>
 </body>
</html>
